story of the week
Ipilimumab Alone or Ipilimumab Plus Anti–PD-1 Therapy in Patients With Metastatic Melanoma Resistant to Anti–PD-(L)1 Monotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ipilimumab Alone or Ipilimumab Plus Anti-PD-1 Therapy in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy: A Multicentre, Retrospective, Cohort Study
Lancet Oncol 2021 May 11;[EPub Ahead of Print], I Pires da Silva, T Ahmed, ILM Reijers, AM Weppler, A Betof Warner, JR Patrinely, P Serra-Bellver, C Allayous, J Mangana, K Nguyen, L Zimmer, C Trojaniello, D Stout, M Lyle, O Klein, CL Gerard, O Michielin, A Haydon, PA Ascierto, MS Carlino, C Lebbe, P Lorigan, DB Johnson, S Sandhu, SN Lo, CU Blank, AM Menzies, GV LongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.